Total Payments
$510,589
2024 Payments
$105,601
Companies
24
Transactions
397
Medicare Patients
2,223
Medicare Billing
$282,354
Payment Breakdown by Category
Other$256,915 (50.3%)
Consulting$199,371 (39.0%)
Travel$45,330 (8.9%)
Food & Beverage$8,785 (1.7%)
Education$187.99 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $229,638 | 50 | 45.0% |
| Consulting Fee | $199,371 | 78 | 39.0% |
| Travel and Lodging | $45,330 | 101 | 8.9% |
| Honoraria | $27,277 | 11 | 5.3% |
| Food and Beverage | $8,785 | 154 | 1.7% |
| Education | $187.99 | 3 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | $168,288 | 124 | $0 (2024) |
| GENZYME CORPORATION | $130,597 | 69 | $0 (2024) |
| Dova Pharmaceuticals | $62,514 | 27 | $0 (2021) |
| SOBI, INC | $59,723 | 33 | $0 (2024) |
| Rigel Pharmaceuticals, Inc. | $36,047 | 42 | $0 (2024) |
| Agios Pharmaceuticals, Inc. | $23,331 | 25 | $0 (2024) |
| Alnylam Pharmaceuticals Inc. | $13,222 | 8 | $0 (2022) |
| Apellis Pharmaceuticals, Inc. | $6,860 | 7 | $0 (2024) |
| BioMarin Pharmaceutical Inc. | $4,694 | 3 | $0 (2020) |
| Kedrion Biopharma Inc. | $2,634 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $105,601 | 120 | Alexion Pharmaceuticals, Inc. ($61,126) |
| 2023 | $129,469 | 102 | Alexion Pharmaceuticals, Inc. ($56,595) |
| 2022 | $140,115 | 104 | Sobi, Inc ($47,319) |
| 2021 | $80,945 | 36 | Dova Pharmaceuticals ($59,514) |
| 2020 | $36,015 | 14 | GENZYME CORPORATION ($11,721) |
| 2019 | $14,041 | 13 | Alnylam Pharmaceuticals Inc. ($6,847) |
| 2018 | $4,319 | 7 | Alexion Pharmaceuticals, Inc. ($4,319) |
| 2017 | $85.00 | 1 | Incyte Corporation ($85.00) |
All Payment Transactions
397 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Food and Beverage | In-kind items and services | $25.81 | General |
| Category: HEMATOLOGY | ||||||
| 12/19/2024 | SOBI, INC | DOPTELET (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,625.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/06/2024 | SOBI, INC | DOPTELET (Drug) | Travel and Lodging | Cash or cash equivalent | $111.10 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/03/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,340.00 | General |
| Category: Rare Disease | ||||||
| 12/03/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $14.92 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $20.64 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $5.06 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 11/14/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $4.85 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 11/01/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $21.62 | General |
| Category: Immunology | ||||||
| 10/25/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $29.02 | General |
| Category: Iron Deficiency Anemia | ||||||
| 10/10/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $881.00 | General |
| 10/10/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $440.50 | General |
| 10/07/2024 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Food and Beverage | In-kind items and services | $23.86 | General |
| Category: HEMATOLOGY | ||||||
| 09/27/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $18.54 | General |
| Category: Oncology | ||||||
| 09/26/2024 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $27.95 | General |
| Category: Oncology | ||||||
| 09/25/2024 | RECORDATI_RARE_DISEASES_INC. | SYLVANT (Drug) | Food and Beverage | In-kind items and services | $18.64 | General |
| Category: ONCOLOGIC AGENT | ||||||
| 09/16/2024 | SOBI, INC | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $29.51 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 09/12/2024 | Alexion Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $99.45 | General |
| 08/28/2024 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Food and Beverage | In-kind items and services | $19.55 | General |
| Category: HEMATOLOGY | ||||||
| 08/21/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $18.61 | General |
| Category: Immunology | ||||||
| 08/19/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $22.71 | General |
| Category: Oncology | ||||||
| 08/08/2024 | Alexion Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $198.90 | General |
| 08/08/2024 | Alexion Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $105.00 | General |
| 08/08/2024 | Alexion Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $70.00 | General |
| 08/08/2024 | Alexion Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $49.72 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 727 | 933 | $325,743 | $83,755 |
| 2022 | 8 | 710 | 909 | $339,200 | $87,388 |
| 2021 | 7 | 554 | 777 | $273,875 | $78,237 |
| 2020 | 6 | 232 | 334 | $126,465 | $32,974 |
Total Patients
2,223
Total Services
2,953
Medicare Billing
$282,354
Procedure Codes
36
All Medicare Procedures & Services
36 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 194 | 240 | $94,062 | $23,829 | 25.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 115 | 175 | $66,325 | $17,552 | 26.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 120 | 182 | $45,864 | $12,197 | 26.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 48 | 57 | $31,655 | $7,702 | 24.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 87 | 110 | $30,056 | $7,613 | 25.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 48 | 48 | $26,544 | $6,736 | 25.4% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 30 | 30 | $12,704 | $3,365 | 26.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 17 | 17 | $9,027 | $2,207 | 24.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 11 | 11 | $4,994 | $1,216 | 24.3% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 22 | 24 | $3,888 | $1,043 | 26.8% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 35 | 39 | $624.00 | $296.79 | 47.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 182 | 222 | $90,768 | $23,178 | 25.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 160 | 234 | $77,922 | $20,446 | 26.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 133 | 197 | $45,704 | $11,935 | 26.1% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 86 | 86 | $38,356 | $9,973 | 26.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 44 | 54 | $31,640 | $8,024 | 25.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 32 | 32 | $20,736 | $5,424 | 26.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 13 | 13 | $9,529 | $2,507 | 26.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 23 | 31 | $8,726 | $2,405 | 27.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 18 | 19 | $9,120 | $2,400 | 26.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 19 | 21 | $6,699 | $1,096 | 16.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 202 | 391 | $120,037 | $34,198 | 28.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 74 | 74 | $44,918 | $12,713 | 28.3% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 66 | 66 | $27,390 | $7,846 | 28.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 94 | 124 | $26,784 | $7,598 | 28.4% |
About Dr. Srikanth Nagalla, MD
Dr. Srikanth Nagalla, MD is a Hematology & Oncology healthcare provider based in Miami, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/01/2008. The National Provider Identifier (NPI) number assigned to this provider is 1902068778.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Srikanth Nagalla, MD has received a total of $510,589 in payments from pharmaceutical and medical device companies, with $105,601 received in 2024. These payments were reported across 397 transactions from 24 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($229,638).
As a Medicare-enrolled provider, Nagalla has provided services to 2,223 Medicare beneficiaries, totaling 2,953 services with total Medicare billing of $282,354. Data is available for 4 years (2020–2023), covering 36 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Miami, FL
- Active Since 07/01/2008
- Last Updated 07/14/2022
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1902068778
Products in Payments
- Doptelet (Drug) $66,413
- DOPTELET (Drug) $55,824
- ULTOMIRIS (Biological) $39,678
- Tavalisse (Drug) $35,833
- CABLIVI (Biological) $27,098
- PYRUKYND (Drug) $23,309
- Ultomiris (Drug) $12,500
- SOLIRIS (Drug) $8,856
- Empaveli (Drug) $6,808
- GIVLARRI (Drug) $4,307
- GIVLAARI (Drug) $3,200
- KOATE (Biological) $2,634
- ENJAYMO (Biological) $1,197
- MONOFERRIC (Drug) $293.48
- Rezlidhia (Drug) $214.55
- REBLOZYL (Biological) $122.11
- ELIQUIS (Drug) $114.99
- JAKAFI (Drug) $104.46
- SYLVANT (Drug) $80.11
- Fabhalta (Drug) $72.25
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Miami
Dr. Steven Fein, M.d, M.D
Hematology & Oncology — Payments: $1.4M
Hematology & Oncology $1.4M
Carl Landgren, Md, MD
Hematology & Oncology — Payments: $751,068
Hematology & Oncology $751,068
Dr. Fernando De Zarraga, M.d, M.D
Hematology & Oncology — Payments: $649,574
Hematology & Oncology $649,574
Mr. Neil Nagovski, Md, MD
Hematology & Oncology — Payments: $533,284
Hematology & Oncology $533,284
Raja Mudad, Md, MD
Hematology & Oncology — Payments: $442,163
Hematology & Oncology $442,163
Mikkael Sekeres, Md, MD
Hematology & Oncology — Payments: $383,274
Hematology & Oncology $383,274